This could be huge:
Press Release Source: Martin Nutraceuticals Inc.
Martin Nutraceuticals Inc. Finalizing Agreement for Marketing and Distribution Rights for CGY-25(R) in Canada and the United States
Thursday February 22, 4:05 pm ET
RENO, Nev.--(BUSINESS WIRE)--Martin Nutraceuticals Inc. (PINKSHEETS: MNCL - News) today announced the finalizing of an agreement for distribution rights of CGY-25® with NormallyPharma for Canada, and is in final negotiations for the distribution rights for the United States.
CGY-25 is for the treatment of male testosterone deficiency also commonly referred to as andropause. CGY-25 stimulates the secretion of a male sex hormone in the Leydig cells for the natural treatment of testosterone deficiency. It is estimated that testosterone deficiency or andropause directly affects more than 11 million men in North America and is believed to have a correlation with Erectile Dysfunction (ED), which affects upwards of 30 million North American men. Treatment of (ED) and other related erectile deficiency's is a $3.5+B business today via prescribed drugs, most notably, Viagra, Cialis and Levitra. Despite the dominance of these products, several opportunities exist for a successful market entry.
According to the market research firm ImpactRx, which tracks the habits of a panel of high prescribing physicians and may reflect emerging trends in doctors' offices today. Upon the introduction of a NEW drug (Cialis) for (ED) in 2004, U.S. urologists initiated treatment with Cialis at a rate of more than two-to-one over each of the other oral ED treatments. In fact, the NEW drug, Cialis, represented 56 percent of new treatment initiations by urologists compared to 21 percent for Levitra and 23 percent for Viagra.
Testosterone Deficiency is characterized by symptoms of fatigue, negative moods and loss of sex drive. Only 5% of men suffering from testosterone deficiency are being treated in North America today. "Men need to understand that the symptoms of low testosterone are not an irreversible element of the aging process. Testosterone deficiency is a medical condition that can be treated successfully," said Dr. Alvaro Morales, Professor of Urology at Queen's University.
CGY-25 has demonstrated improvements in mood and libido and has restored testosterone to normal physiological levels and further studies have shown that CGY-25 properties have shown to help generate the liver. This product and it's properties are in direct contrast to the many side affects the FDA warns about on other ED type drugs including negative side affects to the liver. Also, these other popular drugs make no claims regarding the enhancement of mood, libido or testosterone restoration giving CGY-25 a distinct advantage throughout this sector.
"This agreement not only strengthens the competitive position of CGY-25 (MARTINEX) in North America, but gives Martin Nutraceuticals the ability to penetrate a multi-billion dollar market segment," states Harvey Panesar, President of Martin Nutraceuticals Inc. "We also maintain the integrity of our corporate objective of finding the best possible, all natural products, that help individuals in creating a better lifestyle and we believe that CGY-25 will do that."
CGY-25® will be available shortly through the Martin Nutraceuticals Inc. website
surf's up......crikey
